Rana McKay, MD introduces a metastatic castration-resistant prostate cancer (mCRPC) patient case featuring a 72-year-old man with a history of metastatic castration-resistant prostate cancer.
A 72-Year-Old Man with Metastatic Castration-Resistant Disease
Dr McKay shares her initial impressions of an mCRPC patient case before discussing typical patient treatment protocols, NCCN guidelines, and standard therapeutic options.
Subject matter expert reviews key trial data from recent years and explains how these data impact the prostate cancer treatment landscape.
Rana McKay, MD engages with critical gaps in mCRPC patient care, comments on promising clinical trials, and shares clinical pearls for community oncologists treating patients with mCRPC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
